**Patient Discharge Summary**

**Patient Details:**  
- Name: John Doe  
- Age: 52 years  
- Gender: Male  
- Admission Date: October 1, 2023  
- Discharge Date: October 15, 2023  
- Admitting Physician: Dr. Emily Stanton, MD, Endocrinology  
- Hospital: Saint Michael's Endocrinology Center  

**Chief Complaint:**  
The patient presented with symptoms of polydipsia, polyuria, and unexplained weight loss over the past 3 months.

**History of Present Illness:**  
John Doe, a 52-year-old male with a history of hypertension and hyperlipidemia, was admitted to the endocrinology unit on October 1, 2023, with complaints consistent with hyperglycemia. He reported significant fatigue, increased thirst, frequent urination, and a weight loss of approximately 10 kg over the last three months. No previous diagnosis of diabetes was reported.

**Physical Examination:**  
Upon admission, the patient appeared moderately dehydrated. Vital signs were stable with a blood pressure of 130/85 mmHg, heart rate of 88 bpm, and a BMI of 29 kg/m^2. A comprehensive foot examination revealed no ulcers or sensory deficits.

**Diagnostic Testing:**  
- **Fasting Plasma Glucose (FPG):** 240 mg/dL   
- **Glycosylated Hemoglobin (HbA1C):** 9.8%  
- **Random Glucose Test:** 280 mg/dL on October 2, 2023  
- **Oral Glucose Tolerance Test (OGTT):** Not performed due to conclusive diagnosis from FPG and HbA1C levels.  
- **Urine Test for Albuminuria:** Negative  
- **Serum Creatinine:** Within normal limits  
- **Lipid Profile:** Elevated LDL cholesterol  

Based on the diagnostic findings, John Doe was diagnosed with type 2 diabetes mellitus. Additional screenings for diabetic complications were initiated, including foot and funduscopic examinations, which showed no immediate concerns.

**Hospital Course:**  
The patient underwent diabetes education focusing on the causes of diabetes, recognizing symptoms and signs of hypoglycemia and hyperglycemia, dietary recommendations, and the importance of physical activity. A tailored diet plan emphasizing whole foods and high-quality carbohydrates was introduced, and the patient was encouraged to engage in at least 150 minutes of moderate aerobic exercise per week.

**Medications Initiated:**  
- **Metformin:** Initiated at 500 mg twice daily, with plans to titrate based on tolerance and glycemic control.
- **GLP-1 Receptor Agonist:** Semaglutide was initiated at 0.25 mg once weekly for four weeks, with an intended increase to 0.5 mg as tolerated, focusing on glycemic control and weight management.

**Follow-Up and Recommendations:**  
- The patient was educated on the importance of monitoring blood glucose levels daily, adjusting insulin doses as needed, and recognizing the signs of hypo- and hyperglycemia.  
- A follow-up appointment with Dr. Emily Stanton is scheduled for November 15, 2023, to reassess glycemic control and adjust the treatment regimen as necessary.  
- Regular podiatric care was recommended, and vaccinations for Streptococcus pneumoniae, influenza, hepatitis B, varicella, and SARS-CoV-2 were updated.  
- The patient was advised on the potential benefits of medical devices and surgical treatments for obesity and was referred to a nutritionist for further dietary counseling.

**Discharge Instructions:**  
John Doe was discharged on October 15, 2023, with a comprehensive diabetes management plan, including medications, dietary recommendations, and exercise. He was provided with a glucose monitoring device and instructed on its use. Additionally, the importance of regular physician visits, eye examinations, and podiatric care was emphasized to prevent complications associated with diabetes.

**Summary:**  
John Doe, a newly diagnosed type 2 diabetes patient, was managed with a combination of medication, education, and lifestyle modifications during his hospital stay. A follow-up with his endocrinologist is imperative to monitor his progress and adjust his treatment plan accordingly. Continuous education on diabetes management and its complications will be crucial in his journey to achieving optimal glycemic control and preventing secondary complications.